Study of ropeginterferon alfa-2b for polycythemia vera
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how well a drug called ropeginterferon alfa-2b works for people with polycythemia vera. It aims to understand the drug's effects and safety when used as a first or later treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with polycythemia vera according to 2016 World Health Organization criteria
- You are 18 years old or older
- You need treatment to reduce blood cell counts and ropeginterferon alfa-2b is a possible option, either as your first treatment or after other treatments
- You do not have any medical reason that makes ropeginterferon alfa-2b unsafe for you
- You are willing and able to sign a consent form to participate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a medicine called ropeginterferon alfa-2b for people with polycythemia vera (a blood condition) who do not have a swollen spleen that causes symptoms. It looks at how well the medicine works and how it affects your daily life through simple questionnaires.
This trial tests a medicine called peginterferon for people with two blood disorders: essential thrombocythemia (too many platelets) and polycythemia vera (too many red blood cells). The goal is to see if peginterferon can help control these conditions and is safe.
This Phase 2 trial tests a combination of pegylated interferon and ruxolitinib in adults with polycythemia vera who can’t tolerate hydroxyurea or don’t respond well to it. If you qualify, it may help control blood counts and disease symptoms when standard treatment hasn’t worked.
This Phase 3 study compares ruxolitinib against hydroxycarbamide or interferon as the first treatment for people with high-risk polycythemia vera. It aims to see which option works better to reduce disease-related problems and complications.
This trial tests an experimental pill called bomedemstat for people with polycythemia vera who have not responded well to or could not tolerate hydroxyurea. It aims to see if the drug can help control red blood cell counts with fewer side effects.
This trial tests an investigational drug called rusfertide for people with polycythemia vera whose red blood cell levels are not well controlled. It aims to see if rusfertide can help manage your condition without needing as many phlebotomies (blood removal procedures).
Hear when a new Polycythemia Vera trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.